News | July 16, 2012

Cleveland Clinic Researchers Receive $4.78 Million Grant to Discover Novel Pathways Contributing to Heart Disease

Study builds on research team's prior work linking gut flora to heart disease

July 16, 2012 — The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $4.78 million grant to researchers at Cleveland Clinic’s Lerner Research Institute to use metabolomics — a new approach that focuses on the small-molecule byproducts of metabolism —  for discovery of novel pathways linked to the development of cardiovascular diseases.

“Despite the identification of numerous genetic and clinical risk factors for cardiovascular disease, we can still only explain in a small fraction of patients why that individual develops the disease; this means many novel pathways contributing to the disease still remain unexplored,” said Stanley Hazen, M.D., Ph.D., vice chair of theLerner Research Institute and section head of Preventive Cardiology & Rehabilitation in the Miller Family Heart and Vascular Institute.

Hazen is co-principal investigator on the study with W.H. Wilson Tang, M.D., director of the Cardiomyopathy Program at Cleveland Clinic, and research director of the Section of Heart Failure and Cardiac Transplantation Medicine in the Miller Family Heart and Vascular Institute.

With the NHLBI grant,  Hazen and his colleagues will extend their research by further analyzing the thousands of metabolites in blood, including many that are formed by gut flora, in order to discover pathways linked to causing heart attacks, strokes, and heart failure. They also propose to manipulate the bacteria in humans, testing whether specific probiotics can play a role in treatment of cardiovascular disease. The research can thus ultimately lead to new treatments, including diets and drugs, for cardiovascular disease as well as improved diagnostics and prevention.

Cleveland Clinic’s grant (NHLBI grant number: 1P20HL113452-01) is part of a series awarded by the National Institutes of Health to study the abnormal metabolism of cardiovascular and lung diseases. In addition to Hazen and Tang, the research team includes co-investigator Zeneng Wang, Ph.D., of Cleveland Clinic; Oliver Fiehn, M.D., of the University of California, Davis; and David Lefer, Ph.D., of Emory University.

For more information: www.clevelandclinic.org

 

Related Content

American Heart Association, Verily and AstraZeneca Launch One Brave Idea Science Innovation Center
News | Cardiac Diagnostics| October 20, 2017
The American Heart Association, Verily and AstraZeneca announced the opening of the One Brave Idea Science Innovation...
Cardiovascular Risk Significantly Higher in Women With Fatty Liver Disease
News | Womens Healthcare| October 20, 2017
Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular...
Analytics 4 Life Raises $25 Million for AI-Backed Cardiac Imaging Technology
News | Advanced Visualization| October 20, 2017
October 20, 2017 — Digital health company Analytics 4 Life announced it has completed a $25 million Series B financin
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
The Role of Telomere Length in Cardiovascular Risk Assessment
Feature | Cardiac Diagnostics| October 19, 2017 | Nanette H. Bishopric, M.D., FACC, FAHA
A new area of DNA testing involving telomere length may enhance a patient’s cardiovascular disease risk stratificatio
Appropriate Use Criteria Published for Valvular Heart Disease Imaging Tests
News | Clinical Decision Support| October 16, 2017
The American College of Cardiology (ACC), along with several partnering societies, recently released appropriate use...
Videos | Cardiovascular Ultrasound| October 12, 2017
Sharon Mulvagh, M.D., FRCPC, FACC, FAHA, FASE, professor, Division of Cardiology, Department of Medicine, Dalhouse Un
SunTech Medical Receives Third-Party Validation of CT40 BP Spot-Check Device
News | Blood Pressure Monitor| October 11, 2017
October 11, 2017 — The CT40 spot-check device from SunTech Medical has received third-party validation for...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Majority of High-Risk Stroke Patients Not Being Screened for Common Risk Factors
News | Stroke| September 28, 2017
September 28, 2017 — New research revealed that on average, more than 75 percent of people aged 65 and older worldwid
Overlay Init